We appreciate the comments of Dr Mark R. Goldstein in reference to our recent article1 on HMG-CoA reductase inhibitors and the risk of cancer in which he highlights important issues. We agree that our study does not provide risk data for long-term exposure to HMG-CoA reductase inhibitors since our median follow-up time was only 2.7 years.
Blais L, Desgagné A, LeLorier J. Reductase Inhibitors and the Risk of Cancer—Reply. Arch Intern Med. 2001;161(11):1460. doi: